Certolizumab
As of the edition of 20 October 2026, Certolizumab is an antibody: marketed, first approved in 2010 (CH); acts on TNF.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Antibody
- Brand name
- Cimzia
- First approved
- 11 June 2010 (CH)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- UCB-Pharma SA
- Registered trials
- 14, 2 stopped early
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Immune system; Heart and blood vessels; Cancer; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNF | Tumor necrosis factor | P01375 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 3 | 1 | 1 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 1 | 2 | 0 |
| Phase 3 | 2 | 0 | 1 | 1 |
| Phase 4 | 2 | 0 | 1 | 0 |
| All trials | 14 |